Published on 24/12/2025
Understanding the AllTrials Campaign: Its Progress, Impact, and Ongoing Challenges
What Is the AllTrials Campaign and Why Was It Launched?
Launched in 2013, the AllTrials campaign became a defining movement in the fight for full transparency in clinical research. Led by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, AllTrials raised global awareness of the problem of hidden and unreported clinical trial results—particularly those with negative or inconclusive outcomes.
The core slogan, “All Trials Registered. All Results Reported.”, crystallized the campaign’s demands for better transparency, improved access to data, and global policy reform. The concern was not academic—non-publication of trial data leads to evidence gaps in medicine, flawed systematic reviews, biased clinical guidelines, and ultimately, suboptimal patient care.
Founding Members and Their Vision
The campaign’s founding members were influential: Cochrane brought its evidence synthesis legacy; BMJ added editorial authority; and Ben Goldacre, through Bad Pharma, revealed pharmaceutical industry shortcomings. The mission was clear:
- Ensure that all clinical trials are registered in a public database before patient recruitment begins
- Mandate reporting of all trial results, regardless of outcomes
- Encourage retrospective registration and disclosure of past trials
- Push for enforceable legislation across jurisdictions
The campaign filled a void left by
Milestones Achieved by the Campaign
The AllTrials campaign has achieved significant global visibility and policy impact over the last decade:
- Over 750 organizations signed the AllTrials petition, including medical societies, research funders, and ethics boards
- EMA’s Policy 0070 and EU Clinical Trial Regulation (EU CTR 536/2014) emerged around the same period, supporting proactive disclosure
- Tools like the FDAAA TrialsTracker were developed to monitor sponsor compliance
- Major journals like The Lancet and BMJ made trial registration a prerequisite for publication
Some companies, such as GSK and Johnson & Johnson, pledged to publish trial results proactively. The UK Health Research Authority (HRA) enforced reporting of all trials approved after 2018.
Public Engagement and Open Data Advocacy
Beyond the policy sphere, AllTrials galvanized public support with a petition that received more than 90,000 signatures globally. This grassroots activism sent a clear message to sponsors and regulators: society demands accountability.
The campaign also aligned itself with broader open data and open science movements, promoting reusable datasets and transparency across disciplines. Many academic institutions were prompted to retrospectively register trials and update their result disclosure practices to avoid reputational harm.
Academic Impact and Journal Response
The campaign influenced academic policy significantly. The International Committee of Medical Journal Editors (ICMJE) reinforced its position on trial registration as a publication condition. Guidelines like CONSORT were updated to emphasize complete and timely results disclosure. Systematic reviews began flagging risk of bias due to missing data more aggressively.
Studies also started evaluating transparency metrics. For instance, a PLOS Medicine analysis in 2020 showed that trial reporting among top-tier research institutions improved post-AllTrials, though gaps remain in smaller, investigator-initiated studies.
Challenges and Barriers to Full Compliance
Despite its success, the campaign faces key barriers:
- Enforcement is weak – Legal penalties for non-compliance remain rare outside the U.S.
- Legacy data is inaccessible – Pre-2007 trials remain largely unpublished, and efforts to retrieve those datasets are underfunded
- Resource gaps at small sponsors – Investigator-led trials often lack administrative support for registration and reporting
- Lack of harmonization – Registries like ClinicalTrials.gov, EU CTR, and ICTRP differ in their formats, making global compliance complex
Efforts to address these gaps continue, with transparency advocates lobbying for tougher laws and better sponsor accountability scorecards. Projects like ClinicalStudies.in are helping train institutions in practical compliance tools and global registry management.
Ongoing Monitoring and Compliance Tools
Transparency monitoring has evolved with technology. Platforms like TranspariMED, EU TrialsTracker, and WHO’s ICTRP now offer dashboards to benchmark disclosure by sponsor, country, and funder. Some regulators have started naming and shaming non-compliant institutions, creating reputational incentives for transparency.
Meanwhile, institutions like PharmaValidation.in are developing SOPs and compliance templates for consistent reporting, reducing administrative burden on research sponsors.
Conclusion: A Campaign That Reshaped Clinical Research Norms
The AllTrials campaign permanently changed how clinical research is conducted, reviewed, and disseminated. From patient advocacy to policy reform and journal mandates, the campaign has made a lasting mark.
However, transparency is a continuous journey. The next decade will require stricter enforcement, smarter registries, and full data accessibility—especially in underrepresented regions. The AllTrials legacy remains a blueprint for future movements fighting for ethical, evidence-based science in public health.
To explore global guidelines aligned with AllTrials values, visit the ICH Quality Guidelines and related transparency publications from PharmaRegulatory.in.